share_log

Prime Medicine, Inc.'s Quiet Period Set To Expire on November 29th (NYSEARCA:PRME)

Prime Medicine, Inc.'s Quiet Period Set To Expire on November 29th (NYSEARCA:PRME)

總理醫學, 公司. '的安靜期將於 11 月 29 日到期（紐約證券代碼：PRME）
Financial News Live ·  2022/11/30 09:53

Prime Medicine's (NYSEARCA:PRME – Get Rating) quiet period will end on Tuesday, November 29th. Prime Medicine had issued 10,294,118 shares in its public offering on October 20th. The total size of the offering was $175,000,006 based on an initial share price of $17.00. During the company's quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

總理醫學（紐西爾卡：PRME-獲取評級）安靜期將在 11 月 29 日星期二結束。主健醫藥於十月二十日在其公開發售中發行了 10,294,118 股股份。根據 17 美元的初始股價，該發行的總規模為 175,000 萬美元。在公司的安靜期間，由於 SEC 法規，在 IPO 上工作的內部人員和承銷商無法為公司發布任何盈利預測或研究報告。在公司安靜期結束後，預計擔任該股票承銷商的經紀公司將啟動對該公司的研究覆蓋。

Analyst Ratings Changes

分析師等級變更

Several research analysts have recently commented on the company. Morgan Stanley assumed coverage on Prime Medicine in a research report on Monday, November 14th. They issued an "equal weight" rating and a $23.00 target price for the company. JPMorgan Chase & Co. started coverage on shares of Prime Medicine in a report on Monday, November 14th. They set an "overweight" rating and a $27.00 target price on the stock. Jefferies Financial Group assumed coverage on shares of Prime Medicine in a report on Monday, November 14th. They issued a "buy" rating and a $25.00 price target for the company. Finally, The Goldman Sachs Group assumed coverage on shares of Prime Medicine in a research note on Monday, November 14th. They set a "neutral" rating and a $22.00 price objective on the stock.

幾位研究分析師最近對該公司發表了評論。摩根士丹利在 11 月 14 日星期一的一份研究報告中承擔了優質醫學的報導。他們為該公司發布了「同等權重」評級和 23.00 美元的目標價格。摩根大通公司於 11 月 14 日（星期一）在一份報告中開始對優質醫療股份的報導。他們設定了「超重」評級和 27.00 美元的股票目標價格。富瑞金融集團於 11 月 14 日（星期一）的一份報告中承擔優越醫學股份的覆蓋範圍。他們為該公司發布了「買入」評級和 25.00 美元的目標價格。最後，高盛集團在 11 月 14 日星期一的研究報告中承擔了優質醫藥股份的覆蓋範圍。他們對股票設定了「中立」評級和 22.00 美元的價格目標。

Get
取得
Prime Medicine
主要醫學
alerts:
警報：

Prime Medicine Price Performance

主要醫藥價格表現

Shares of NYSEARCA:PRME traded down $0.11 on Tuesday, reaching $17.33. 227,386 shares of the company traded hands, compared to its average volume of 340,970. Prime Medicine has a fifty-two week low of $14.52 and a fifty-two week high of $21.73. The company's 50 day moving average is $19.34 and its 200-day moving average is $19.91.

紐約證券交易所股票週二下跌 0.11 美元，達到 17.33 美元。該公司的 227,386 股交易手，相比其平均交易量為 340,970。優質醫藥有五十二周的低點 14.52 美元，五十二周高點為 21.73 美元。該公司的 50 日移動平均線為 19.34 美元，其 200 天移動平均線為 19.91 美元。

Insider Buying and Selling at Prime Medicine

主要醫藥的內幕購買和銷售

In other news, Director Thomas Cahill purchased 400,000 shares of the company's stock in a transaction dated Monday, October 24th. The shares were bought at an average price of $17.00 per share, with a total value of $6,800,000.00. Following the completion of the transaction, the director now directly owns 5,305,679 shares in the company, valued at approximately $90,196,543. The purchase was disclosed in a filing with the SEC, which is available through
在其他消息中，董事托馬斯·卡希爾（Thomas Cahill）在 10 月 24 日（星期一）的一項交易中購買了該公司股票的 400,000 股。這些股票以每股 17.00 美元的平均價格買入，總價值為 6,800,000.00 美元。交易完成後，董事現直接擁有該公司 5,305,679 股股份，價值約為 90,196,543 元。該購買在與 SEC 提交的文件中披露，該文件可通過以下方式獲得
this link
這個鏈接
. In other Prime Medicine news, major shareholder 2019 Gp L.L.C. Gv acquired 800,000 shares of Prime Medicine stock in a transaction dated Monday, October 24th. The stock was bought at an average cost of $17.00 per share, with a total value of $13,600,000.00. Following the completion of the transaction, the insider now owns 11,522,248 shares of the company's stock, valued at $195,878,216. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through
。在其他主要醫藥新聞中，主要股東大股東集團有限責任公司在 10 月 24 日（星期一）的一項交易中收購了 80 萬股優質醫藥股票。該股票以每股 17.00 美元的平均成本買入，總價值為 13,600 美元。交易完成後，內幕人士現在擁有該公司股票的 11,522,248 股股份，價值為 195,878,216 美元。該收購已在向證券交易委員會提交的文件中披露，該文件可通過以下方式獲得
the SEC website
證券交易所網站
. Also, Director Thomas Cahill acquired 400,000 shares of Prime Medicine stock in a transaction dated Monday, October 24th. The stock was acquired at an average cost of $17.00 per share, with a total value of $6,800,000.00. Following the completion of the transaction, the director now directly owns 5,305,679 shares of the company's stock, valued at approximately $90,196,543. The disclosure for this purchase can be found
。此外，董事托馬斯·卡希爾（Thomas Cahill）在 10 月 24 日（星期一）的一項交易中收購了 40 萬股優質醫藥股票。該股票以每股 17.00 美元的平均成本收購，總價值為 6,800,000.00 美元。交易完成後，董事現直接擁有該公司股票 5,305,679 股股份，價值約為 90,196,543 元。可以找到此次購買的披露
here
這裡
.
。

About Prime Medicine

關於主健醫學

(Get Rating)

(取得評分)

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

Prime 醫學公司是一家生物技術公司，通過部署基因編輯技術提供遺傳療法以解決疾病。它為 Prime Editor 提供了 Prime Editor 蛋白質，包括 Cas 蛋白質和逆轉錄酶之間的融合；以及一個 peGrNA，它將 Prime 編輯器定位到特定的基因組位置，並提供了一個模板，用於對目標 DNA 序列進行所需編輯。

Read More

閱讀更多

  • Get a free copy of the StockNews.com research report on Prime Medicine (PRME)
  • Three Reasons It's Time To Get Bullish On Organigram
  • Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
  • Why Investors Are Eating Up Restaurant Brands International
  • Zoom Video Continues to Work Through Normalization
  • What an Inverted Yield Curve Means for Investors
  • 免費獲取有關主要醫學研究報告的副本
  • 三個原因是時候看漲有機圖
  • 機會罷工！Hibbett, 公司在強勁的結果下跌平坦
  • 為什麼投資者正在吃飯餐廳品牌國際
  • 縮放視頻繼續通過正常化工作
  • 反向收益率曲線對投資者意味著什麼

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

接收主要醫學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Prime Medicine 和相關公司的最新新聞和分析師評級的簡要每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論